- Details
- Neal Shore, MD, FACS joins Alicia Morgans, MD, MPH to discuss the outcomes of the CARD trial, Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD) in a recent analysis presented at the AUA 2020 Virtual...
|
- Details
- Cora Sternberg, MD, FACP, shares her experiences from the CARD study, which was the first trial to evaluate the sequencing of the androgen-signaling–targeted inhibitor (abiraterone or enzalutamide) compared to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) who had been previously treated with docetaxel and the alternative androgen-signaling–targeted agent (abi...
|
- Details
- William Oh and Stephen Freedland join Alicia Morgans to discuss the efficacy and safety in older patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide an analysis of the CARD Trial. Prostate cancer is the 2nd and 3rd leading cause of cancer death in the USA and in Europe, respectively, with most deaths occurring in men over t...
|
- Details
- Lead author of the TRITON-2 study, Wassim Abida joins Charles Ryan to talk about the recent approval of rucaparib, the first PARP Inhibitor approved for men with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA mutation. This approval was based on findings from the TRITON-2 study, rucaparib for post-chemotherapy mCRPC patients who have previously received one AR-targe...
|
- Details
- Alicia Morgans and Christopher Sweeney discuss the IMbassador250 trial results presented at the AACR 2020 virtual meeting. IMbassador250 is a phase III trial in patients with metastatic castration-resistant prostate cancer (mCRPC) comparing atezolizumab plus enzalutamide vs enzalutamide alone. Dr. Sweeney says that the study conclusively showed that adding atezolizumab to enzalutamide after abirat...
|
- Details
- Charles Ryan invites Rahul Aggarwal to discuss treatment-emergent small-cell neuroendocrine prostate cancer, an area not well characterized in the era of modern androgen receptor (AR)-targeting therapy. This study was funded by Stand Up to Cancer and the Prostate Cancer Foundation. Patients with metastatic castration-resistant prostate cancer were enrolled in which metastatic tumor biopsies were p...
|
- Details
- Alicia Morgans and Charles Ryan highlight the breaking news that the Food and Drug Administration (FDA) approved the first PARP Inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA mutation. Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-res...
|
- Details
- The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED) (NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Oliver Sartor, the primary author joins Alicia Morgans to provide an update on the PROCEED registry aiming to understand outcomes for Afr...
|
- Details
- In an area where we have multiple options for treatment and we continue to have more data that helps to guide us, Evan Yu joins Alicia Morgans to speak about drug sequencing in the metastatic castration-resistant prostate cancer (mCRPC) setting and his approach to moving a patient through the different phases of treatment. Biographies: Evan Yu, MD, Medical oncologist, treats prostate, bladder, and...
|
- Details
- The ORIOLE Phase 2 Randomized Clinical Trial set out to answer the question, "how effectively does stereotactic ablative radiotherapy prevent progression of disease compared with observation in men with recurrent hormone-sensitive prostate cancer with 1 to 3 metastases?" Dr. Tran joins Alicia Morgans and discusses this phase 2 randomized clinical trial of 54 men, where the progression of disease a...
|
